Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...
Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...
Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...
It depends. There have been a few clinical trials on the impact of GLP-1 injectable medications on weight loss with different ...
Nanoscope has received a new patent ( US Patent No. 12459977) from the US Patent and Trademark Office (USPTO) for the company’s Multi-Characteristic Opsin (MCO) technology platform as a novel and ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback